Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Navigating a 22% Revenue Growth with a Promising PipelineAurinia Pharmaceuticals Inc (NASDAQ: AUPH), a Canadian biopharmaceutical company, has garnered considerable attention in the healthcare sector, particularly within the biotechnology industry. **Current Market Landscape**As of its latest trading session, Aurinia Pharmaceuticals’ stock trades at $13.07, marking the upper limit of its 52-week range between $6.75 and $13.07. **Analyst Ratings and Price Targets**Investor sentiment surrounding Aurinia Pharmaceuticals is predominantly positive, with six buy ratings, one hold rating, and no sell ratings. Analysts have set a target price range between $9.00 and $17.00, with an average target of $11.71. For investors seeking a foothold in the biotechnology sector, Aurinia Pharmaceuticals presents a compelling case with its focused approach to addressing autoimmune diseases.